Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Switzerland Approves Moderna's COVID-19 Shot For Kids 6-11
The Swiss drug regulatory authority has approvedModerna Inc's(NASDAQ:MRNA) COVID-19 vaccine for children ages 6-11.
The approval is for the vaccine's two-dose series of 50 micrograms per dose, Moderna added.
Shares were up 6.72% at $138.92 Friday.
Neurocrine's Huntington's Candidate Secures FDA Orphan Drug Tag
The FDA has granted Orphan Drug Designation toNeurocrine Biosciences Inc's(NASDAQ:NBIX) valbenazine for Huntington's disease (HD).
The treatment of chorea associated with...
Login or create a forever free account to read this news
Sign up/Log in